Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Ovarian Neoplasms 1Neoplasms, Second Primary 1NSCLC 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Kidney Neoplasms 1Gastro Intestinal Stromal Tumor 1Endometrial Neoplasms 1Congenital Abnormalities 1Asymptomatic Brain Metastases 1

Interventions

Varenicline 1Tyrosine Kinase Inhibitors 1Trastuzumab 1Tobacco Use Cessation Devices 1Registries 1Patient Reported Outcome Measures 1Nicotine Chewing Gum 1Interviews as Topic 1Cisplatin 1Bupropion 1Bleomycin 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Second Primary × Tyrosine Kinase Inhibitors × 1 year × Clear all
NCT04151342 2025-12-03

CARMA-BROS

University Health Network, Toronto

Recruiting
5,500 enrolled

Congenital Abnormalities, Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡